BLASubcutaneousInjectablePriority Review
Approved
Dec 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
9
Data completeness
5/8 — Partial
Priority Review
ALHEMO (concizumab) by Novo Nordisk is tissue factor pathway inhibitor antagonists [moa]. Approved for tissue factor pathway inhibitor antagonist [epc]. First approved in 2024.
Drug data last refreshed 22h ago
Mechanism of Action
Tissue Factor Pathway Inhibitor Antagonists
Pharmacologic Class:
Tissue Factor Pathway Inhibitor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (9)
Post-marketing Surveillance (Special Use-results Surveillance) on Treatment With Alhemo
Started May 2025
30 enrolled
Haemophilia A, Haemophilia B
Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors
Started Aug 2024
23 enrolled
Haemophilia AHaemophilia B
A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors
Started Mar 2022
153 enrolled
Haemophilia A and B With and Without Inhibitors
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
Started Nov 2019
156 enrolled
Haemophilia A Without InhibitorsHaemophilia B Without Inhibitors
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors
Started Oct 2019
134 enrolled
Haemophilia A With InhibitorsHaemophilia B With Inhibitors
Worked on ALHEMO at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.